8 Key Applications Of Real-World Data In Multiple Myeloma Therapy Development

Multiple myeloma (MM) remains a challenge in the field of hematologic malignancies due to its genetic complexity and varied clinical manifestations. Despite significant progress in therapeutic options, including proteasome inhibitors and monoclonal antibodies, issues such as drug resistance and relapse are prevalent. The integration of real-world data is critical for advancing MM research and treatment strategies. Here we explore 8 key use cases where these datasets can be leveraged.

Quest Diagnostics provides a pivotal resource through its extensive therapeutic area (TA) datasets, encompassing over 1.8 million patient records. These datasets, including the Test-Based and Patient-Centric Cohorts, are instrumental for applications like clinical trial recruitment, patient journey analysis, and real-world evidence generation. They facilitate insights into treatment pathways, biomarker discovery, and cytogenetic abnormalities, crucial for developing targeted MM therapies. Quest Diagnostics' expansive test offerings, supported by specialized subsidiaries like Athena Diagnostics, cater to complex diagnostic needs, enhancing research capabilities in MM. By embracing collaboration, Quest aims to accelerate transformative MM treatment developments, reinforcing its role in advancing hematologic cancer research.